Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 65

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 65
---
 transition to a new presidential administration in the United States, including the potential use and effects
of tariffs to address the administration’s policy goals, could materially impact our costs and revenues, as well as the macroeconomic
framework in which we operate; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products;
product development and related clinical trials and validation studies; results from our products under development may not be successful
or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in Childhood Onset Growth Hormone
Deficiency (“ CGHD AGHD NASDAQ TSX

These
risk factors are not intended to represent a complete list of the risk factors that could affect the Company. These factors and assumptions,
however, should be considered carefully. More detailed information about these and other factors is included under “ Risk Factors”
in this Annual Report on Form 20-F and in other documents incorporated herein by reference.

However,
we advise you to review any further disclosures we make on related subjects in our reports on Form 6-K filed or furnished to the SEC
and in our other public disclosure filed under our profile on SEDAR+ at www. sedarplus. com.

Although
the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in
forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Many of these
factors are beyond our control. There can be no assurance that such statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such statements, particularly in light of any resulting impacts on the global
economy and on the Company’s business. Accordingly, readers should not place undue reliance on forward-looking statements. The
Company does not undertake to update any forward-looking statements contained herein, except as required by applicable securities laws.
New factors emerge from time to time, and it is not possible for the Company to predict all of these factors, or to assess in advance
the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statement.

  45  

About
Material Information

This
MD& A includes information that we believe to be material to investors after considering all circumstances. We consider information
and disclosures to be material if they result in, or would reasonably be expected to result in